Experimental Chewing Gum Reduces Oral HPV By Up To 93% In Lab Tests

An experimental gum trapped up to 93% of HPV in saliva samples from head and neck cancer patients. This chewing gum oral HPV research comes from a 2026 University of Pennsylvania lab study. Researchers treated samples with gum extracts, and no patient chewed the gum. The product remains experimental.

TL;DR

• Penn researchers mixed bean gum extracts with patient saliva and aggregated about 93% of HPV.

• A protegrin-1 version cut two cancer-linked bacteria by more than 99% in lab samples.

• The study measured microbes in samples and did not test infection, cancer risk, or survival.

• The team plans human trials, and the gum is not sold or approved for use.

What Did Researchers Discover About HPV And Chewing Gum?

Henry Daniell at Penn Dental Medicine led the work with colleagues from Kansas, UCLA, and the VA. The paper in Scientific Reports came out in February 2026. Penn announced it in April, and coverage resurfaced in August and November.

The team collected saliva and oral-rinse samples from 44 patients with head and neck squamous cell carcinoma (HNSCC). HPV showed up in every saliva sample and 75% of rinse samples. Researchers then treated the samples with gum extracts and measured what remained.

Aggregation means the gum protein clumped virus particles together. The 93% figure describes viral trapping in a lab tube. It says nothing yet about clearing an infection from a person.

How Does The Experimental Chewing Gum Work?

The gum has two active parts, each aimed at different microbes. Both were tested as extracts from research formulations.

FRIL: The Bean-Derived Antiviral Protein

The base gum is made from lablab beans, which contain a sugar-binding protein called FRIL. Daniell told MedicalResearch.com that FRIL has four binding sites. They grab sugar chains on the virus surface. One FRIL molecule can hold several particles, so viruses get stuck in large clumps.

Why Researchers Added Protegrin-1

Protegrin-1 is an antimicrobial peptide first found in pig white blood cells. It punches holes in bacterial membranes. The team bioengineered the bean gum to carry it. This product has little in common with xylitol chewing gum, which lowers cavity risk by starving decay bacteria.

Why Are Researchers Targeting Oral HPV?

Persistent infection with high-risk HPV, mainly HPV-16, causes most oropharyngeal cancers in the US, according to the National Cancer Institute. These tumors form in the tonsils, base of the tongue, and back of the throat.

Oral cavity cancers on the lips, gums, and front of the tongue are more often tied to tobacco and alcohol. Saliva carries HPV, so the mouth is a logical place to trap it. The study did not show that lowering oral HPV prevents cancer. See our guide to oral cancer symptoms and risk factors for background.

What Happened To The Oral Bacteria Tested?

The bacterial results come from separate tests with the protegrin-1 formulation. Porphyromonas gingivalis is a keystone pathogen in periodontitis. Fusobacterium nucleatum links early and late plaque colonizers and turns up inside oral tumors.

Daniell said both infections worsen survival in recurrent or metastatic oral cancer. One dose of the extract cut both species by more than 99% in samples from 42 patients. The study did not measure gum health, bleeding, or cancer outcomes.

Did The Experimental Gum Affect Beneficial Oral Bacteria?

Broad antiseptics wipe out helpful species along with harmful ones. Protegrin-1 killed the two anaerobes and spared capsule-forming bacteria, including streptococci. Many streptococci are health-associated early colonizers of tooth surfaces.

Penn contrasted this with radiation therapy, which cuts beneficial bacteria and lets Candida albicans grow. That shift is familiar to anyone managing radiation therapy and dental health. The team tested selected species only, so the data cannot confirm the whole microbiome stays intact in people.

Can Chewing Gum Prevent Or Treat Oral Cancer?

No study has shown that this gum, or any chewing gum, prevents or treats oral cancer. Clinical evidence usually builds in three stages.

• Ex vivo tests show what an extract does to patient samples in the lab.

• Early human studies check safety and whether the effect holds during real chewing.

• Controlled trials measure outcomes such as infection clearance, lesion progression, and survival.

The FRIL gum has completed only the first stage. HPV vaccination remains the proven way to prevent HPV-related cancers, per the CDC. Exams that follow the oral cancer screening guidelines still catch lesions early. A sore or lump lasting more than two weeks needs a clinical exam, and no gum should delay cancer care.

What Needs To Happen Before This Gum Could Be Used By Patients?

Daniell said the planned trial will test three gums a day for four weeks and track HPV viral load. Open questions include:

• Whether FRIL is released from the gum at useful levels during normal chewing

• Whether repeated daily use is safe and well tolerated

• Whether viral load drops in living patients

• Whether lower viral load changes infection, lesion, or cancer outcomes

• Which regulatory pathway a gum-carrying biologic protein would need

The gum has no regulatory approval and is not on the market.

What Does The Study Mean For Dentistry?

The gum is a local delivery system. Chewing keeps a protein in contact with saliva and mucosa for many minutes, at home and without a needle. Daniell has proposed antiviral gum early, antibacterial gum during mucositis, and antifungal gum after radiation.

If trials succeed, such gums could join a patient's dental treatment plan next to screening and periodontal care. Salivary viral load is a cheap, repeatable research measure. A lower number still has to be tied to fewer infections or cancers before it changes care. The work adds to research on the oral virome, the viruses living in the mouth.

"A drop in HPV inside a sample shows the protein can grab the virus," says dentist and co-founder at Dental Reviewed, Darius Kucinas. "An established infection lives inside the cells lining the tonsils and throat. Gum that traps virus floating in saliva may never reach those cells."

He notes that viral load is a useful early signal for researchers. "Cancer takes years to develop. The real test is whether lower numbers change who gets sick." Before recommending antiviral gum, he would want trials in patients who chew it for weeks. "I'd look for safety data, repeat HPV tests over time, and fewer persistent infections."

"Patients shouldn't read this as a reason to chew more gum from the store shelf," Kucinas adds. "Ordinary gum contains no FRIL. HPV vaccination and regular screening are what protect them today."

Bottom Line

Experimental gum extracts trapped up to 93% of HPV in saliva and cut two cancer-linked bacteria by more than 99% in patient samples. The results are promising for a low-cost delivery idea. They do not show that chewing gum prevents or treats oral cancer in people. Human trials will decide whether the approach has a place in care.